Jafron Biomedical Co

Jafron Biomedical Co CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Jafron Biomedical Co (300529.SZ) as of Nov 13, 2026 is 23.93 %. In the previous year, CapEx to Operating Cash Flow Ratio was 22.37 % — a change of 6.96% (higher).

CapEx/OCF

23.93 %

YoY

6.96%

Last updated:

CapEx to Operating Cash Flow Ratio of Jafron Biomedical Co is 2025 23.93 % . CapEx to Operating Cash Flow Ratio of Jafron Biomedical Co was 2024 22.37 % . It decreases by 6.96% higher compared to the previous year.

The Jafron Biomedical Co CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
45.18 CNY
Jan 1, 2019
37.82 CNY
Jan 1, 2020
37.30 CNY
Jan 1, 2021
43.01 CNY
Jan 1, 2022
53.85 CNY
Jan 1, 2023
26.97 CNY
Jan 1, 2024
22.37 CNY
Jan 1, 2025
23.93 CNY
The Jafron Biomedical Co CapEx/OCF history
YEARCapEx/OCFYoY
23.93 %+6.96%
22.37 %-17.05%
26.97 %-49.91%
53.85 %+25.18%
43.01 %+15.33%
37.30 %-1.38%
37.82 %-16.29%
45.18 %-22.70%
58.44 %+264.35%
16.04 %-46.40%
29.93 %-36.06%
46.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

CapEx to Operating Cash Flow Ratio of Jafron Biomedical Co is 23.93 % in 2025.

CapEx to Operating Cash Flow Ratio of Jafron Biomedical Co changed from 22.37 % to 23.93 %, representing a 6.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Jafron Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Jafron Biomedical Co

All Key Metrics — Jafron Biomedical Co